The development of VIP-ellipticine conjugates

Regulatory Peptides

Volumn 123, Issue 1-3 SPEC. ISS., 2004, Pages 187-192

  Moody, Terry W ^a   Czerwinski, Gregory ^b   Tarasova, Nadia I ^b   Moody, Deborah L ^b   Michejda, Christopher J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ALALA; alanyl leucyl alanyl leucyl alanine; E; ellipticine; G; glycine; LALA; Lung cancer; PACAP; pituitary adenylate cyclase activating polypeptide; vasoactive intestinal peptide; VIP; VIP agonists; VIP ellipticine derivatives; VPAC1 receptor

Indexed keywords

ALANYLLEUCYLALANYLLEUCYLALANINE; CYCLIC AMP; ELLIPTICINE; IODINE 125; LEUCYLALANYLLEUCYLALANINE; THYMIDINE; TRITIUM; TRYPAN BLUE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL LINE; CELL VIABILITY; CYTOTOXICITY; DRUG DOSE; ENDOCYTOSIS; GROWTH INHIBITION; IC 50; IN VITRO STUDY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; DRUG DESIGN; ELLIPTICINES; ENDOCYTOSIS; HUMANS; LUNG NEOPLASMS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; THYMIDINE; VASOACTIVE INTESTINAL PEPTIDE;

CORVUS HAWAIIENSIS;

EID: 7044222132     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.03.021     Document Type: Article

References (21)

1. Said S.I., Mutt V. Polypeptide with broad biological activity: isolation from the small intestine. Science. 69:1970;1217-1218
2. Gozes I., McCune S.L., Jacobson L., Warren D., Moody T., Fridkin M., et al. A hybrid antagonist to vasoactive intestinal peptide. Effects on cellular function in the central nervous system. J. Pharmacol. Exp. Ther. 257:1991;959-966
3. Moody T.W., Hill J.M., Jensen R.T. VIP as a trophic factor in the CNS and cancer cells. Peptides. 24:2003;163-177
4. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul. Pept. 37:1992;287-303
5. Ishihara R., Shigemoto R., Mori K., Takahashi K., Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron. 8:1992;811-819
6. Harmar T., Lutz E.M. Multiple receptors for PACAP and VIP. Trends Pharmacol. Sci. 15:1993;97-99
7. Pisegna J.R., Wank S.A. Multiple cloning and functional expression of the pituitary adenylate cyclase activating polypeptide type: I. Receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6345-6349
8. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeberg P.H., et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 365:1993;170-175
9. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., et al. Breast cancer growth is inhibited by VIPhybrid, a synthetic VIP receptor antagonist. Cancer Res. 56:1996;3486-3489
10. Whitmarsh A.J., Davies R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:1996;589-607
11. Moody T.W., Zia F., Draoui M., Brenneman D.E., Fridkin M., Davidson A., et al. A novel VIP antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. U. S. A. 90:1993;4345-4349
12. Moody T.W., Czerwinski G., Tarasova N.I., Michejda C.J. VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci. 19:2002;1005-1014
13. Czerwinski G.C., Tarasova N.I., Michejda C. Cytotoxic agents directed to peptide hormone receptors. Defining the requirements for a successful drug. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11520-11525
14. Korman L.Y., Carney D.N., Citron M., Moody T.W. Secretin/VIP stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung. Cancer Res. 46:1986;1214-1218
15. 13,14)bombesin analogues inhibit the growth of small cell lung cancer in vitro and in vivo. Cancer Res. 51:1991;1298-1802
16. Fahrenkrug J. Glycine-extended processing intermediate of proVIP: a new bioactive form of VIP in the rat. Biomed. Res. 13(Sup. 2):1992;19-23
17. Thakur M.L., Marcus C.S., Saeed S., Pallela V., Minami C., Diggles L., et al. Imaging tumors in humans with Tc-99m-VIP. Ann. N. Y. Acad. Sci. 921:2000;37-44
18. Reubi J.C., Laderach U., Waser B., Gebbers J.D., Robberecht P., Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60:2000;3105-3112
19. Rivalle C., Wendling R., Tambourin P., Lhoste J.M., Bisafni E., Cherman J.C. Antitumor animo-substituted pyrido (3′,4′-4,5) pyrrolo (2,3-g)isoquinolines and pyrido (4,3-β)carbazole derivatives: synthesis and evaluation of compounds resulting from new side chains and heterocyclic modifications. J. Med. Chem. 26:1983;181-185
20. Schiller J.H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., et al. Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 14:1996;2345-2352
21. Tarasova N.I., Stauber R.H., Choi J.K., Hudson E.A., Czerwinski G., Miller J.L., et al. Visualization of G protein-coupled receptor trafficking with the aid of green fluorescent protein. Endocytosis and recycling of cholecystokinin receptor type A. J. Biol. Chem. 272:1997;14817-14824